Aviragen Therapeutics, Inc. (AVIR) Stock Rating Reaffirmed by HC Wainwright

Aviragen Therapeutics, Inc. (NASDAQ:AVIR)‘s stock had its “hold” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Tuesday.

COPYRIGHT VIOLATION WARNING: “Aviragen Therapeutics, Inc. (AVIR) Stock Rating Reaffirmed by HC Wainwright” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/02/aviragen-therapeutics-inc-avir-stock-rating-reaffirmed-by-hc-wainwright.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Carlson Capital Management bought a new stake in shares of Aviragen Therapeutics during the second quarter valued at approximately $105,000. Virtu KCG Holdings LLC bought a new stake in shares of Aviragen Therapeutics during the second quarter valued at approximately $149,000. Finally, FMR LLC increased its position in shares of Aviragen Therapeutics by 115.3% during the first quarter. FMR LLC now owns 1,002,500 shares of the biotechnology company’s stock valued at $653,000 after purchasing an additional 536,799 shares during the period. Institutional investors and hedge funds own 24.20% of the company’s stock.

Aviragen Therapeutics Company Profile

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Aviragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply